What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements
March 05 - Mar 06, 2024

WCRI

Healthesystems is attending the Workers Compensation Research Institute Issues & Research Conference for senior-level decision makers from across the workers' compensation spectrum.

Boston, MA
March 18 - Mar 20, 2024

CO WCEC

Healthesystems is attending the Colorado Workers' Compensation Education Conference for stakeholders in Colorado workers' comp.

Broadmoor, CO
View all Events

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Zepbound (tirzepatide) injection

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

hello world!

Zituvimet (sitagliptin and metformin hydrochloride) tablets

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

hello world!

Voquezna (vonoprazan fumarate) tablets

Approval Date: Nov 2023

Note: New Product

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

hello world!

Zymfentra (infliximab-dyyb) injection

Approval Date: Oct 2023

Note: New Product

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

hello world!

Omvoh (mirikizumab-mrkz) injection

Approval Date: Oct 2023

Note: New Product

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

hello world!

Wezlana (ustekinumab-auub) injection

Approval Date: Oct 2023

Note: Biosimilar

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

hello world!

Velsipity (estrasimod) tablets

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe ulcerative colitis

hello world!

Cosentyx® (secukinumab) injection for intravenous use

Approval Date: Oct 2023

Note: New Dosage or Formulation

Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation

hello world!

Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

hello world!

Combogesic® IV (acetaminophen and ibuprofen)

Approval Date: Oct 2023

Note: Dosage or Formulation

Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation

hello world!
1 2 3 11

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmagnifiermenucross-circle